{"id":39582,"date":"2026-08-17T08:46:27","date_gmt":"2026-08-17T06:46:27","guid":{"rendered":"https:\/\/ggba.swiss\/oculis-acquires-worldwide-rights-to-its-privosegtor-candidate\/"},"modified":"2026-08-17T08:48:53","modified_gmt":"2026-08-17T06:48:53","slug":"oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/","title":{"rendered":"Oculis acquiert les droits mondiaux sur son candidat Privosegtor"},"content":{"rendered":"\n

Oculis<\/a>, une entreprise biopharmaceutique sp\u00e9cialis\u00e9e en ophtalmologie et neuro-ophtalmologie, va acqu\u00e9rir aupr\u00e8s d’Accure l’ensemble des droits mondiaux de d\u00e9veloppement et de commercialisation du Privosegtor, l’un de ses deux candidats principaux. L’op\u00e9ration entra\u00eenera la fin de l’accord de licence existant entre les deux soci\u00e9t\u00e9s, y compris les paiements d’\u00e9tape et redevances associ\u00e9s \u00e0 chaque indication aboutie.<\/p>\n\n\n\n

Le Privosegtor est un candidat pepto\u00efde de petite mol\u00e9cule qui franchit les barri\u00e8res h\u00e9mato-enc\u00e9phalique et h\u00e9mato-r\u00e9tinienne, avec le potentiel de devenir une premi\u00e8re th\u00e9rapie neuroprotectrice contre la n\u00e9vrite optique et d’autres maladies neuro-ophtalmiques et neuro-axonales. Les r\u00e9sultats de l’essai de phase 2 ACUITY ont mis en \u00e9vidence son potentiel neuroprotecteur, avec des am\u00e9liorations de la fonction visuelle corrobor\u00e9es par la pr\u00e9servation anatomique de la r\u00e9tine et une baisse des taux de neurofilaments dans le sang apr\u00e8s un \u00e9pisode aigu de n\u00e9vrite optique. Des r\u00e9sultats coh\u00e9rents ont \u00e9t\u00e9 observ\u00e9s dans des mod\u00e8les animaux de glaucome, de n\u00e9vrite optique et de scl\u00e9rose en plaques.<\/p>\n\n\n\n

Le candidat est actuellement \u00e9valu\u00e9 dans le cadre du programme PIONEER de l’entreprise, qui comprend deux essais d’enregistrement dans la n\u00e9vrite optique et un dans la neuropathie optique isch\u00e9mique ant\u00e9rieure non art\u00e9ritique. S’appuyant sur les donn\u00e9es d’ACUITY et sur les retours pr\u00e9-IND de la FDA, Oculis pr\u00e9voit \u00e9galement une demande d’autorisation de nouveau m\u00e9dicament exp\u00e9rimental pour le traitement des pouss\u00e9es aigu\u00ebs de scl\u00e9rose en plaques.<\/p>\n\n\n\n

Aux termes de l’accord d’acquisition d’actifs, Oculis acquerra les droits d’Accure sur le Privosegtor (ACT-01) lors d’une premi\u00e8re cl\u00f4ture et, s\u00e9par\u00e9ment, sur ACT-02, un candidat pr\u00e9clinique en neurologie \u00e0 un stade pr\u00e9coce. La contrepartie totale des deux op\u00e9rations comprend un paiement initial en num\u00e9raire de USD 3,8 millions (CHF 3,1 millions) et jusqu’\u00e0 2’050’000 actions ordinaires Oculis, dont une partie est soumise \u00e0 l’atteinte d’\u00e9tapes de d\u00e9veloppement et r\u00e9glementaires. La cl\u00f4ture pour le Privosegtor est attendue au plus tard le 28 f\u00e9vrier 2027, et celle pour ACT-02 au plus tard le 31 mars 2027.<\/p>\n","protected":false},"excerpt":{"rendered":"

Oculis, l’entreprise biopharmaceutique lausannoise sp\u00e9cialis\u00e9e en ophtalmologie et neuro-ophtalmologie, va acqu\u00e9rir aupr\u00e8s d’Accure l’ensemble des droits mondiaux de d\u00e9veloppement et de commercialisation du Privosegtor, mettant fin \u00e0 son accord de licence existant.<\/p>\n","protected":false},"author":6,"featured_media":39579,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1188,1154,1171,1142],"class_list":["post-39582","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-healthcare-fr-2","tag-investment-fr-2","tag-pharma-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"\nOculis acquiert tous les droits sur son candidat Privosegtor<\/title>\n<meta name=\"description\" content=\"Oculis acquiert l'ensemble des droits mondiaux de d\u00e9veloppement et de commercialisation de son candidat Privosegtor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oculis acquiert tous les droits sur son candidat Privosegtor\" \/>\n<meta property=\"og:description\" content=\"Oculis acquiert l'ensemble des droits mondiaux de d\u00e9veloppement et de commercialisation de son candidat Privosegtor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-17T06:46:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-17T06:48:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Oculis-AI-Eye-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Oculis acquiert les droits mondiaux sur son candidat Privosegtor\",\"datePublished\":\"2026-08-17T06:46:27+00:00\",\"dateModified\":\"2026-08-17T06:48:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/\"},\"wordCount\":391,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Oculis-AI-Eye-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Healthcare\",\"Investment\",\"Pharma\",\"R&D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/\",\"name\":\"Oculis acquiert tous les droits sur son candidat Privosegtor\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Oculis-AI-Eye-1180x811-1.png\",\"datePublished\":\"2026-08-17T06:46:27+00:00\",\"dateModified\":\"2026-08-17T06:48:53+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Oculis acquiert l'ensemble des droits mondiaux de d\u00e9veloppement et de commercialisation de son candidat Privosegtor.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Oculis-AI-Eye-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Oculis-AI-Eye-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"Oculis d\u00e9veloppe des th\u00e9rapies contre les maladies ophtalmiques et neuro-ophtalmiques, dont le Privosegtor, un candidat contre la n\u00e9vrite optique.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oculis acquiert les droits mondiaux sur son candidat Privosegtor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oculis acquiert tous les droits sur son candidat Privosegtor","description":"Oculis acquiert l'ensemble des droits mondiaux de d\u00e9veloppement et de commercialisation de son candidat Privosegtor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/","og_locale":"fr_FR","og_type":"article","og_title":"Oculis acquiert tous les droits sur son candidat Privosegtor","og_description":"Oculis acquiert l'ensemble des droits mondiaux de d\u00e9veloppement et de commercialisation de son candidat Privosegtor.","og_url":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-08-17T06:46:27+00:00","article_modified_time":"2026-08-17T06:48:53+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Oculis-AI-Eye-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Oculis acquiert les droits mondiaux sur son candidat Privosegtor","datePublished":"2026-08-17T06:46:27+00:00","dateModified":"2026-08-17T06:48:53+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/"},"wordCount":391,"image":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Oculis-AI-Eye-1180x811-1.png","keywords":["Biotech","Healthcare","Investment","Pharma","R&D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/","url":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/","name":"Oculis acquiert tous les droits sur son candidat Privosegtor","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Oculis-AI-Eye-1180x811-1.png","datePublished":"2026-08-17T06:46:27+00:00","dateModified":"2026-08-17T06:48:53+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Oculis acquiert l'ensemble des droits mondiaux de d\u00e9veloppement et de commercialisation de son candidat Privosegtor.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Oculis-AI-Eye-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Oculis-AI-Eye-1180x811-1.png","width":1180,"height":811,"caption":"Oculis d\u00e9veloppe des th\u00e9rapies contre les maladies ophtalmiques et neuro-ophtalmiques, dont le Privosegtor, un candidat contre la n\u00e9vrite optique."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/oculis-acquiert-les-droits-mondiaux-sur-son-candidat-privosegtor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Oculis acquiert les droits mondiaux sur son candidat Privosegtor"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=39582"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39582\/revisions"}],"predecessor-version":[{"id":39584,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39582\/revisions\/39584"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/39579"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=39582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=39582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=39582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}